Glucocorticoid induced hyperglycaemia and the development of type 2 diabetes mellitus are major downsides to the use of steroids for the treatment of acute and chronic inflammatory diseases. In a randomised controlled trial Professor Tomlinson and colleagues working with Professor Holman and the Diabetes Trials Unit have investigated whether AZD4017, an 11ß-HSD1 inhibitor, can attenuate glucocorticoid-associated side effects on blood pressure, glycaemia, bone, and lipid metabolism, assessed after 7 days therapy in healthy men....
[Read more...]The trial Targeting Iatrogenic Cushing's Syndrome with 11ß-hydroxysteroid dehydrogenase type 1 Inhibition (TICSI) met its recruitment target by enrolling 32 participants since June 2017. The last study visit took place on 27th February 2019....
[Read more...]The first patient has been randomised into the TICSI trial.